[Federal Register Volume 68, Number 63 (Wednesday, April 2, 2003)]
[Notices]
[Page 16088]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-7824]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 22, 2003, Cedarburg 
Pharmaceuticals, LLC, 870 Badger Circle, Grafton, Wisconsin 53204, made 
application by letter to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of dihydromorphine (9145), a basic 
class of controlled substance listed in Schedule I.
    The firm plans to use this substance in the conversion processes to 
produce Schedule II hydromorphone.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Drug Operations Section, Domestic Drug 
Unit (ODOD) and must be filed no later than June 2, 2003.

    Dated: March 14, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-7824 Filed 4-1-03; 8:45 am]
BILLING CODE 4410-09-M